Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A challenge for clinical biomarker testing

The use of immune checkpoint inhibitors (ICI) targeting the PD-L1:PD1 interaction revolutionized tumor treatment by re-activating the anti-tumoral capacity of the immune system. Assessment of tumor mutational burden, microsatellite instability, or expression of the surface marker PD-L1 have been use...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolb, Tobias, Benckendorff, Julian, Möller, Peter, Barth, Thomas F.E., Marienfeld, Ralf B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976464/
https://www.ncbi.nlm.nih.gov/pubmed/36812781
http://dx.doi.org/10.1016/j.neo.2023.100884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976464/
https://www.ncbi.nlm.nih.gov/pubmed/36812781
http://dx.doi.org/10.1016/j.neo.2023.100884

Ejemplares similares